Here's Why Amphastar (AMPH) is Poised for a Turnaround After Losing 13.1% in 4 Weeks

Amphastar Pharmaceuticals (AMPH) has recently declined 13.1% over four weeks, pushing its Relative Strength Index (RSI) to 29.97, indicating an oversold condition. This technical signal, combined with a 3.4% increase in consensus EPS estimates over the past 30 days and a Zacks Rank #2 (Buy), suggests the stock is poised for a near-term turnaround.

Analysis

Amphastar Pharmaceuticals (AMPH) has experienced significant selling pressure, resulting in a 13.1% stock price decline over the past four weeks. This downturn has pushed the stock's Relative Strength Index (RSI) to 29.97, a level widely considered to be in oversold territory, which technically suggests the potential for a near-term price reversal as selling momentum may be exhausted. Supporting this technical signal is a positive fundamental development; sell-side analysts have increased the consensus EPS estimate for the current year by 3.4% over the last 30 days. Such upward revisions in earnings estimates are often correlated with subsequent stock price appreciation. The turnaround thesis is further reinforced by the stock's Zacks Rank #2 (Buy), a proprietary rating that identifies the top 20% of stocks based on earnings estimate trends, indicating a confluence of technical and fundamental factors pointing to a potential rebound.

Key Decisions for Investors

• Given the combination of an oversold RSI at 29.97 and a 3.4% increase in consensus EPS estimates, investors could consider the recent 13.1% pullback a potential contrarian entry point.
• The investment thesis is heavily reliant on positive earnings estimate revisions, so investors should closely monitor analyst consensus for any degradation in sentiment, which would challenge the turnaround narrative.
• A prudent strategy would involve confirming the technical bottom suggested by the RSI with other indicators, such as trading volume and price action, before establishing or adding to a position.